Gland Pharma: Should You Buy, Hold, or Sell Right Now?
- September 2, 2026
- Posted by: Lakshit Sharma
- Category: Market
Gland Pharma share price Rs 2,812.50 (NSE), down 2.17% today. 52-week range Rs 1,573.60 to Rs 3,039.80. Q1 FY27 profit up 47.1% YoY to Rs 316.96 crore.
Quick Answer
Gland Pharma share price is trading around Rs 2,813, roughly 7 percent below its 52-week high of Rs 3,039.80 and well above its 52-week low of Rs 1,573.60. Q1 FY27 revenue grew 19.1 percent year on year to Rs 1,861.5 crore, with net profit up 47.1 percent to Rs 316.96 crore, continuing a steady quarter-on-quarter improvement trend. The stock trades at 41.9 times earnings, a modest premium to the pharma sector average near 38 times. Investors who value the company’s complex injectables manufacturing expertise may see the current level as reasonable, while others may want the valuation premium to narrow before adding exposure.
Gland Pharma share price has pulled back modestly from its 52-week high of Rs 3,039.80, with Gland Pharma share price trading near Rs 2,813 on the NSE, well above its 52-week low of Rs 1,573.60. With profit growing sharply faster than revenue in Q1 FY27, investors are asking whether this injectables manufacturer is a stock to buy, hold, or sell after its Q1 FY27 results, a hold, or a stock to watch for continued margin improvement.
This Gland Pharma stock analysis walks through the Q1 FY27 numbers, valuation against the pharmaceutical sector, shareholding pattern and the technical setup, using figures sourced from company disclosures and public filings.
Click Here – Get Free Investment Predictions
About Gland Pharma
Keep this backdrop in mind when reading the rest of this Gland Pharma share price review. Before deciding on Gland Pharma share price, it helps to understand the underlying business. Gland Pharma Ltd. is a leading manufacturer of complex injectable pharmaceuticals, including generics, biosimilars and other specialised formulations, serving customers across the United States, Europe, India and other global markets. The company is majority owned by Shanghai Fosun Pharmaceutical, a large Chinese pharmaceutical conglomerate, which has supported Gland’s expansion into new markets and product categories.
Gland Pharma’s business has been on a steady improvement trajectory over the past several quarters, with both revenue and profit showing consistent sequential growth as the company has expanded its complex generics and biosimilars portfolio.
Gland Pharma Share Price Today: Key Levels
The table below summarises where Gland Pharma share price stands right now against its recent trading range and market value.
| Metric | Value |
|---|---|
| Gland Pharma CMP (NSE) | Rs 2,812.50 |
| Gland Pharma CMP (BSE) | Rs 2,809.90 |
| Day’s Change | -2.17% (Rs -62.50) |
| 52-Week High | Rs 3,039.80 |
| 52-Week Low | Rs 1,573.60 |
| Market Capitalisation | Approximately Rs 47,318 crore |
| NSE Volume (latest session) | 2,72,022 shares |
Gland Pharma share price is trading in the upper half of its 52-week range, reflecting sustained investor confidence following consistent quarter-on-quarter improvement in both revenue and profit.
Check the Univest Screener for Live Stock Data
Gland Pharma Financial Performance
Track this line item closely if you are following Gland Pharma share price closely. The Gland Pharma share price trend is closely tied to how these numbers evolve each quarter. Gland Pharma reported Q1 FY27 (June 2026 quarter) revenue of Rs 1,861.5 crore, up 19.1 percent year on year from Rs 1,563.15 crore, with net profit growing 47.1 percent year on year to Rs 316.96 crore from Rs 215.48 crore. This continues a consistent sequential improvement trend, with quarterly profit rising steadily from Rs 183.68 crore in September 2025 to Rs 366.68 crore in March 2026 before this latest result.
For the full year FY26, Gland Pharma reported revenue of Rs 6,746.98 crore, up 15.7 percent year on year, with net profit of Rs 1,027.32 crore, up 47.1 percent, showing the improvement trend has been sustained over a full year rather than being limited to just the latest quarter.
| Period | Revenue | Net Profit | Comment |
|---|---|---|---|
| Q1 FY27 (Jun 2026) | Rs 1,861.5 crore | Rs 316.96 crore | +19.1% revenue, +47.1% profit YoY |
| FY26 (full year) | Rs 6,746.98 crore | Rs 1,027.32 crore | +15.7% revenue, +47.1% profit YoY |
Valuation Check: Is Gland Pharma Share Price Expensive?
It is one of the clearest signals available on Gland Pharma share price today. Any view on Gland Pharma share price should start from these valuation multiples. Gland Pharma share price currently reflects a price to earnings ratio of about 41.9 times trailing earnings, a modest premium to the broader pharmaceutical sector average of roughly 38 times. The price to book ratio stands near 4.6 times, with return on equity at 9.92 percent, a figure that has been improving as profit growth has outpaced revenue growth.
The company carries essentially no debt, with a debt to equity ratio of just 0.03. Historically, complex injectables manufacturers with sustained margin improvement and strong global customer relationships have commanded valuation premiums, so the current modest premium reflects the market recognising Gland Pharma’s consistent execution over the full FY26 year and into Q1 FY27.
Technical Signals: What the Chart Shows
Price action here often foreshadows the next move in Gland Pharma share price. Gland Pharma share price is currently positioned about 7 percent below its 52-week high of Rs 3,039.80 and roughly 79 percent above its 52-week low of Rs 1,573.60, reflecting a very strong overall run over the past year. A stock trading this close to its annual high, backed by consistent sequential profit improvement, typically signals the market rewarding sustained execution.
Trading volumes remain healthy, so investors should track Gland Pharma share price over the next couple of quarters to confirm the improvement trend continues, rather than reacting to any single day’s move at these technical levels.
Download the Univest iOS App or Univest Android App to track Gland Pharma’s live price and technical levels.
Shareholding Pattern
Shifts here can influence Gland Pharma share price more than headline news on some sessions. Gland Pharma is majority owned by Shanghai Fosun Pharmaceutical, a large Chinese pharmaceutical conglomerate, which has been the company’s controlling shareholder since acquiring a majority stake ahead of Gland Pharma’s Indian stock market listing. A detailed current percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company’s latest exchange filing.
Why Investors Are Watching Gland Pharma
- Sustained profit improvement trend: Profit growth has accelerated consistently over the full FY26 year and into Q1 FY27, rather than being a one-off quarterly result.
- Complex injectables manufacturing expertise: Gland Pharma’s specialisation in complex, harder-to-manufacture injectable formulations provides a differentiated competitive position versus simpler generic manufacturers.
- Global customer base and market access: Exposure to the United States, Europe, India and other markets diversifies Gland Pharma’s revenue base geographically.
- Debt free balance sheet: A debt to equity ratio of just 0.03 gives the company significant financial flexibility to fund continued growth.
Risks and Factors to Watch
- Modest premium valuation: A 41.9x PE, above the sector average, leaves less room for disappointment if the improvement trend were to slow.
- Regulatory risk across multiple markets: As an exporter of complex injectables to the United States, Europe and other regulated markets, Gland Pharma faces ongoing regulatory compliance and inspection risk across jurisdictions.
- Dependence on continued new product approvals: Sustaining growth requires continued successful development and regulatory approval of new complex generic and biosimilar products.
- Majority foreign ownership considerations: Majority ownership by Shanghai Fosun Pharmaceutical means minority shareholders should be attentive to related-party governance and capital allocation decisions over time.
Gland Pharma Share Price Target: What the Data Suggests
Until then, Gland Pharma share price remains best tracked through live, verified data rather than a single fixed number. Gland Pharma does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. What the data shows is a company delivering sustained profit improvement over a full year and into Q1 FY27, trading at a modest premium to the pharmaceutical sector.
Historically, complex injectables manufacturers with consistent execution have sustained or expanded their valuation premiums. Investors who want live, updated research can check the Univest Screener, and should consult a SEBI-registered investment adviser for guidance tailored to their own goals.
Gland Pharma: Should You Buy, Hold, or Sell Right Now?
The Gland Pharma buy or sell decision depends on your confidence in the sustained improvement trend continuing.
The case for buying: Growth-focused investors who value the consistent, sustained profit improvement over a full year and Gland Pharma’s complex injectables expertise may see the current level, near its 52-week high, as justified by fundamentals.
The case for holding: Existing shareholders who already track Gland Pharma’s execution trend may prefer to stay invested through continued strong performance.
The case for trimming or waiting: Valuation-sensitive investors uncomfortable with the modest premium to sector PE may prefer to wait for a pullback before adding fresh exposure.
Historically, well-executed pharmaceutical manufacturers have rewarded patient investors through sustained improvement cycles, so weigh this against your own investment horizon and consult a SEBI-registered investment adviser if unsure.
Conclusion
Gland Pharma share price reflects a complex injectables manufacturer delivering a sustained profit improvement trend across the full FY26 year and into Q1 FY27, trading at a modest premium to the pharmaceutical sector near its 52-week high. Whether that makes the stock a buy, a hold or a sell right now depends on your confidence that the improvement trend can continue. This article is for informational purposes and not a personalised investment recommendation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Q1. Should you buy, hold, or sell Gland Pharma right now?
Ans. Gland Pharma grew Q1 FY27 profit 47.1 percent year on year on 19.1 percent revenue growth, continuing a sustained improvement trend seen through the full FY26 year. The stock trades at a modest premium to the pharma sector, which may appeal to investors who believe in the company’s continued execution.
Q2. What is the Gland Pharma share price today?
Ans. Gland Pharma share price is trading around Rs 2,813 on the NSE, down about 2.17 percent on the day. The stock’s 52-week high is Rs 3,039.80 and its 52-week low is Rs 1,573.60.
Q3. What is the Gland Pharma share price target?
Ans. Gland Pharma does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time. Investors can check live research on the Univest Screener and consult a SEBI-registered adviser.
Q4. Who owns Gland Pharma?
Ans. Gland Pharma is majority owned by Shanghai Fosun Pharmaceutical, a large Chinese pharmaceutical conglomerate, which has been the company’s controlling shareholder since before its Indian stock market listing.
Q5. What is Gland Pharma’s market capitalisation and PE ratio?
Ans. Gland Pharma has a market capitalisation of approximately Rs 47,318 crore and trades at a price to earnings ratio of about 41.9 times, a modest premium to the pharmaceutical sector average PE of roughly 38 times.
Q6. What does Gland Pharma manufacture?
Ans. Gland Pharma manufactures complex injectable pharmaceuticals, including generics and biosimilars, serving customers across the United States, Europe, India and other global markets.